Skin Infection News and Research

RSS

New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

In the battle against stubborn skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), a new single-dose antibiotic is as effective as a twice-daily infusion given for up to 10 days, according to a large study led by Duke Medicine researchers.

5 Jun 2014

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

A study published in today's New England Journal of Medicine reports that the antibiotic dalbavancin is as effective as vancomycin, the current standard-of-care antibiotic used to treat serious bacterial skin and skin-structure infections.

5 Jun 2014

LA BioMed researcher receives APIC Award for Publication Excellence

Loren Miller, MD, a Los Angeles Biomedical Research Institute (LA BioMed) lead researcher, is the senior author of a published study that will receive the Association for Professionals in Infection Control and Epidemiology (APIC) Award for Publication Excellence at its annual conference in Anaheim on June 7.

20 May 2014

Researchers identify novel vancomycin-resistant MRSA superbug in Brazil

An international research team led by Cesar A. Arias, M.D., Ph.D., at The University of Texas Health Science Center at Houston has identified a new superbug that caused a bloodstream infection in a Brazilian patient. The report appeared in the April 17 issue of The New England Journal of Medicine.

17 Apr 2014

Research findings may help combat MRSA

A research team from Vanderbilt University Medical Center in Nashville, Tenn., is the first to decipher the 3-D structure of a protein that confers antibiotic resistance from one of the most worrisome disease agents: a strain of bacteria called methicillin-resistant Staphylococcus aureus (MRSA), which can cause skin and other infections. The Vanderbilt team's findings may be an important step in combatting the MRSA public health threat over the next 5 to 10 years.

17 Feb 2014

Infection contributes to higher risk of stroke death among blacks

Infection is a stronger trigger of stroke death in African- Americans than in whites, a University of Michigan study shows.

9 Feb 2014

New noninvasive chemical probe detects common species of staph bacteria in the body

Chances are you won't know you've got a staph infection until the test results come in, days after the symptoms first appear. But what if your physician could identify the infection much more quickly and without having to take a biopsy and ship it off for analysis?

From Integrated DNA Technologies 3 Feb 2014

Research roundup: Patient safety measure results 'disappointing'

Patient safety poses serious challenges to the health care system in the United States. Since 2001, nationwide efforts have focused on reducing in-hospital adverse events.

25 Jan 2014

Researchers find that uninsured patients are less likely to be transferred to another hospital

Uninsured patients with a variety of common medical diagnoses are significantly less likely to be transferred between hospitals for treatment, according to a new study led by researchers at the University of Pittsburgh School of Medicine in collaboration with researchers at the University of Iowa and University of Toronto.

20 Jan 2014

Study finds significant decline of MRSA infections in VA long-term care facilities

Four years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus rates in Veterans Affairs long-term care facilities, MRSA infections have declined significantly, according to a study in the January issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.

7 Jan 2014

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

Streptococcus biofilms persist on objects, surfaces in daycare center for longer periods after cleaning

Numerous scientific studies have concluded that two common bacteria that cause colds, ear infections, strep throat and more serious infections cannot live for long outside the human body.

27 Dec 2013

Researchers develop new vaccine that protects against lethal pneumonia caused by staph bacteria

University of Iowa researchers have developed a new vaccine that protects against lethal pneumonia caused by Staphylococcus aureus (staph) bacteria, including drug-resistant strains like MRSA.

23 Dec 2013

Scientists reveal how MRSA strain rapidly rises to prominence

Scientists believe they have an explanation for how the most common strain of methicillin-resistant Staphylococcus aureus rapidly rose to prominence. Research published in mBio-, the online open-access journal of the American Society for Microbiology, suggests that the strain recently acquired a number of genes from common skin bacteria that allow it to grow and thrive on the skin where other strains of MRSA cannot.

17 Dec 2013

IBN and IBM discover new medical application for converted PET bottles

Researchers at Singapore's Institute of Bioengineering and Nanotechnology (IBN) and California's IBM Research - Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles.

10 Dec 2013

New material effective in destroying drug-resistant fungi

Researchers at Singapore’s Institute of Bioengineering and Nanotechnology (IBN) and California’s IBM Research – Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles.

9 Dec 2013

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA-both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.

2 Dec 2013